IMPROVE-IT ACC2015依折麦布.pptx

Addressing Cardiovascular Events:;;Educational Objectives;A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin monotherapy in high-risk patients presenting with acute coronary syndrome;Biologic Basis For Lowering LDL-C;LDL HypothesisIs Lowering the LDL Enough, Or Does the Agent Matter?;Determinants of Atherosclerosis;;Study Design;IMPROVE-ITStudy Goals;IMPROVE-ITNot a Placebo Study;;IMPROVE-ITEzetimibe/Simvastatin Reduces Risk of Cardiovascular Events ;IMPROVE-ITSafety Data;Safety of Other LDL Lowering Treatments;Abstract Presented at ACC 2015;Hypothesis;Number of Primary End Point Events;Total Primary End Point Events;What we know about “Lower is Better”;Conclusions;Conclusions;Abbreviations;Abbreviations (cont);References;References (cont);References (cont)